Breast cancer odds ratios (95% confidence intervals) by ER and PR status and CYP1A2*F genotype
| . | n* . | AA . | AC . | CC . | P† . |
|---|---|---|---|---|---|
| ER negative | 205/1,370 | 1.0 | 0.8 (0.6-1.1) | 0.7 (0.4-1.2) | 0.08 |
| ER positive | 703/1,370 | 1.0 | 0.9 (0.8-1.1) | 0.8 (0.6-1.2) | 0.26 |
| PR negative | 269/1,370 | 1.0 | 0.9 (0.7-1.1) | 0.6 (0.4-1.1) | 0.08 |
| PR positive | 605/1,370 | 1.0 | 0.9 (0.7-1.1) | 0.9 (0.6-1.3) | 0.41 |
| ER/PR negative | 165/1,370 | 1.0 | 0.8 (0.5-1.1) | 0.5 (0.3-1.1) | 0.03 |
| ER/PR positive | 562/1,370 | 1.0 | 0.9 (0.8-1.2) | 0.9 (0.6-1.3) | 0.41 |
| . | n* . | AA . | AC . | CC . | P† . |
|---|---|---|---|---|---|
| ER negative | 205/1,370 | 1.0 | 0.8 (0.6-1.1) | 0.7 (0.4-1.2) | 0.08 |
| ER positive | 703/1,370 | 1.0 | 0.9 (0.8-1.1) | 0.8 (0.6-1.2) | 0.26 |
| PR negative | 269/1,370 | 1.0 | 0.9 (0.7-1.1) | 0.6 (0.4-1.1) | 0.08 |
| PR positive | 605/1,370 | 1.0 | 0.9 (0.7-1.1) | 0.9 (0.6-1.3) | 0.41 |
| ER/PR negative | 165/1,370 | 1.0 | 0.8 (0.5-1.1) | 0.5 (0.3-1.1) | 0.03 |
| ER/PR positive | 562/1,370 | 1.0 | 0.9 (0.8-1.2) | 0.9 (0.6-1.3) | 0.41 |
NOTE: Adjusted by logistic regression for age at blood draw, race/ethnicity, age at menarche, parity and age at first birth.
No. cases/no. controls; 431 cases had missing ER status and 465 cases had missing PR status.
P value for gene dosage term assigned 1, 2, and 3 for 0, 1, and 2 variant alleles, respectively. The P value for comparison of gene dosage effects between the ER/PR-negative and ER/PR-positive groups by polytomous logistic regression was not statistically significant (P = 0.13).